header
Image from OpenLibrary

The clinical significance of tissue inhibitors of metalloproteinase -1 and -2 in serum of patients with nonalcoholic fatty liver disease / Kareem Essam Eldin Hadad ; Supervised Rokaya Abdelaziz , Sahar Abdelaaty , Mohamed Elbasel

By: Contributor(s): Material type: TextTextLanguage: English Publication details: Cairo : Kareem Essam Eldin Hadad , 2012Description: 127 P. : facsimiles ; 25cmOther title:
  • الأهميه الاكلينيكيه للمثبطات النسيجيه للمتالوبروتينيز 1 و2 فى مرضى الكبد الدهنى الغير كحولى [Added title page title]
Subject(s): Available additional physical forms:
  • Issued also as CD
Dissertation note: Thesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Internal Medicine Summary: The clinical significance of Tissue Inhibitors of metalloproteinase -1 and -2 in serum of patients with nonalcoholic fatty liver disease. Non alcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease and its incidence is rising worldwide. NAFLD refers to a wide spectrum of liver disease ranging from simple fatty liver (NAFL), to nonalcoholic steatohepatitis (NASH), to cirrhosis. Patients with NASH are at risk for progressive liver disease, emphasizing the clinical importance of developing non-invasive biomarkers for NASH and NASH related fibrosis. Tissue inhibitors of metalloproteinase-1 and -2 (TIMP -1 and -2) were found to be reliable markers for NASH and NASH related fibrosis and are closely linked to the proinflammatory status . In this study we assess the serum level of these two biomarkers in patients with NAFLD. The purpose of this study is to examine the performance of new biomarkers (TIMP -1 and TIMP -2) for NAFL and NASH with a combination of clinical and laboratory variables. This model seems to represent a reliable noninvasive tool in patients with fatty liver disease. 90 subjects were classified into 3 groups: 1) Obese patients with normal liver function (NAFL, n = 30). Obese patients with elevated liver functions (NASH, n = 30). 3) Non obese control group (n = 30). All subjects underwent full medical history, physical examination, body mass index (BMI), fasting blood sugar (FBS), 2 hours postprandial (2HPP), lipid profile, Serum alanine transaminase (ALT), aspartate transaminase (AST), gamma GT levels, alkaline phosphatase (ALP), abdominal ultrasound. Serum TIMP -1 and -2 levels were measured using ELISA. Seven of our patients had liver biopsy
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Home library Call number Copy number Status Date due Barcode
Thesis Thesis قاعة الرسائل الجامعية - الدور الاول المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.11.18.Ph.D.2012.Ka.C (Browse shelf(Opens below)) Not for loan 01010110068886000
CD - Rom CD - Rom مخـــزن الرســائل الجـــامعية - البدروم المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.11.18.Ph.D.2012.Ka.C (Browse shelf(Opens below)) 68886.CD Not for loan 01020110068886000

Thesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Internal Medicine

The clinical significance of Tissue Inhibitors of metalloproteinase -1 and -2 in serum of patients with nonalcoholic fatty liver disease. Non alcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease and its incidence is rising worldwide. NAFLD refers to a wide spectrum of liver disease ranging from simple fatty liver (NAFL), to nonalcoholic steatohepatitis (NASH), to cirrhosis. Patients with NASH are at risk for progressive liver disease, emphasizing the clinical importance of developing non-invasive biomarkers for NASH and NASH related fibrosis. Tissue inhibitors of metalloproteinase-1 and -2 (TIMP -1 and -2) were found to be reliable markers for NASH and NASH related fibrosis and are closely linked to the proinflammatory status . In this study we assess the serum level of these two biomarkers in patients with NAFLD. The purpose of this study is to examine the performance of new biomarkers (TIMP -1 and TIMP -2) for NAFL and NASH with a combination of clinical and laboratory variables. This model seems to represent a reliable noninvasive tool in patients with fatty liver disease. 90 subjects were classified into 3 groups: 1) Obese patients with normal liver function (NAFL, n = 30). Obese patients with elevated liver functions (NASH, n = 30). 3) Non obese control group (n = 30). All subjects underwent full medical history, physical examination, body mass index (BMI), fasting blood sugar (FBS), 2 hours postprandial (2HPP), lipid profile, Serum alanine transaminase (ALT), aspartate transaminase (AST), gamma GT levels, alkaline phosphatase (ALP), abdominal ultrasound. Serum TIMP -1 and -2 levels were measured using ELISA. Seven of our patients had liver biopsy

Issued also as CD

There are no comments on this title.

to post a comment.